The global generic pharmaceuticals contract manufacturing market size is calculated at USD 81.22 billion in 2025 and is forecasted to reach around USD 135.36 billion by 2034, accelerating at a CAGR of 5.84% from 2025 to 2034. The Asia Pacific generic pharmaceuticals contract manufacturing market size accounted for USD 31.68 billion in 2024 and is expanding at a CAGR of 5.98% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Generic Pharmaceuticals Contract Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Generic Pharmaceuticals Contract Manufacturing Market, by Drug
8.1.1. Branded Generics
8.1.1.1. Market Revenue and Forecast
8.1.2. Unbranded Generics
8.1.2.1. Market Revenue and Forecast
9.1. Generic Pharmaceuticals Contract Manufacturing Market, by Product
9.1.1. API
9.1.1.1. Market Revenue and Forecast
9.1.2. Drug Product
9.1.2.1. Market Revenue and Forecast
10.1. Generic Pharmaceuticals Contract Manufacturing Market, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast
10.1.3. Topical
10.1.3.1. Market Revenue and Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Forecast
11.1. Generic Pharmaceuticals Contract Manufacturing Market, by Application
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Immunology
11.1.2.1. Market Revenue and Forecast
11.1.3. Antidiabetic
11.1.3.1. Market Revenue and Forecast
11.1.4. Neurology
11.1.4.1. Market Revenue and Forecast
11.1.5. Anticoagulants
11.1.5.1. Market Revenue and Forecast
11.1.6. Cardiovascular
11.1.6.1. Market Revenue and Forecast
11.1.7. Respiratory
11.1.7.1. Market Revenue and Forecast
11.1.8. Pain
11.1.8.1. Market Revenue and Forecast
11.1.9. HIV antivirals
11.1.9.1. Market Revenue and Forecast
11.1.10. Others
11.1.10.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug
12.1.2. Market Revenue and Forecast, by Product
12.1.3. Market Revenue and Forecast, by Route of Administration
12.1.4. Market Revenue and Forecast, by Application
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug
12.1.5.2. Market Revenue and Forecast, by Product
12.1.5.3. Market Revenue and Forecast, by Route of Administration
12.1.5.4. Market Revenue and Forecast, by Application
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug
12.1.6.2. Market Revenue and Forecast, by Product
12.1.6.3. Market Revenue and Forecast, by Route of Administration
12.1.6.4. Market Revenue and Forecast, by Application
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug
12.2.2. Market Revenue and Forecast, by Product
12.2.3. Market Revenue and Forecast, by Route of Administration
12.2.4. Market Revenue and Forecast, by Application
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug
12.2.5.2. Market Revenue and Forecast, by Product
12.2.5.3. Market Revenue and Forecast, by Route of Administration
12.2.5.4. Market Revenue and Forecast, by Application
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug
12.2.6.2. Market Revenue and Forecast, by Product
12.2.6.3. Market Revenue and Forecast, by Route of Administration
12.2.6.4. Market Revenue and Forecast, by Application
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug
12.2.7.2. Market Revenue and Forecast, by Product
12.2.7.3. Market Revenue and Forecast, by Route of Administration
12.2.7.4. Market Revenue and Forecast, by Application
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug
12.2.8.2. Market Revenue and Forecast, by Product
12.2.8.3. Market Revenue and Forecast, by Route of Administration
12.2.8.4. Market Revenue and Forecast, by Application
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug
12.3.2. Market Revenue and Forecast, by Product
12.3.3. Market Revenue and Forecast, by Route of Administration
12.3.4. Market Revenue and Forecast, by Application
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug
12.3.5.2. Market Revenue and Forecast, by Product
12.3.5.3. Market Revenue and Forecast, by Route of Administration
12.3.5.4. Market Revenue and Forecast, by Application
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug
12.3.6.2. Market Revenue and Forecast, by Product
12.3.6.3. Market Revenue and Forecast, by Route of Administration
12.3.6.4. Market Revenue and Forecast, by Application
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug
12.3.7.2. Market Revenue and Forecast, by Product
12.3.7.3. Market Revenue and Forecast, by Route of Administration
12.3.7.4. Market Revenue and Forecast, by Application
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug
12.3.8.2. Market Revenue and Forecast, by Product
12.3.8.3. Market Revenue and Forecast, by Route of Administration
12.3.8.4. Market Revenue and Forecast, by Application
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug
12.4.2. Market Revenue and Forecast, by Product
12.4.3. Market Revenue and Forecast, by Route of Administration
12.4.4. Market Revenue and Forecast, by Application
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug
12.4.5.2. Market Revenue and Forecast, by Product
12.4.5.3. Market Revenue and Forecast, by Route of Administration
12.4.5.4. Market Revenue and Forecast, by Application
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug
12.4.6.2. Market Revenue and Forecast, by Product
12.4.6.3. Market Revenue and Forecast, by Route of Administration
12.4.6.4. Market Revenue and Forecast, by Application
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug
12.4.7.2. Market Revenue and Forecast, by Product
12.4.7.3. Market Revenue and Forecast, by Route of Administration
12.4.7.4. Market Revenue and Forecast, by Application
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug
12.4.8.2. Market Revenue and Forecast, by Product
12.4.8.3. Market Revenue and Forecast, by Route of Administration
12.4.8.4. Market Revenue and Forecast, by Application
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug
12.5.2. Market Revenue and Forecast, by Product
12.5.3. Market Revenue and Forecast, by Route of Administration
12.5.4. Market Revenue and Forecast, by Application
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug
12.5.5.2. Market Revenue and Forecast, by Product
12.5.5.3. Market Revenue and Forecast, by Route of Administration
12.5.5.4. Market Revenue and Forecast, by Application
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug
12.5.6.2. Market Revenue and Forecast, by Product
12.5.6.3. Market Revenue and Forecast, by Route of Administration
12.5.6.4. Market Revenue and Forecast, by Application
13.1. Metrics Contract Services
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Curia Global, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer Centre One
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Syngene International Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Acme Generics Pvt Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Catalent, Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Alcami Corp., Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Cambrex Corp.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Aurobindo Pharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Siegfried Holding AG
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample